Physician profile
Michael D Smith
NPI 1003819707
$6,749.45
in general payments reported to CMS, 2019-2025
51 companies · $1,072 in 2025
The $1,072 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,622 · 2022: $1,273 · 2023: $1,532 · 2024: $1,250 · 2025: $1,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,854.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,175.14 | 2021-2025 | |
| Novo Nordisk INC | $668.42 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $582.88 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $483.12 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $310.11 | 2021-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $258.57 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $250.36 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $224.19 | 2022-2025 | Rexulti |
| Esperion Therapeutics, INC. | $212.93 | 2021-2024 | Nexletol |
| Amgen INC. | $193.13 | 2022-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $183.32 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $173.19 | 2021-2023 | |
| Pfizer INC. | $142.77 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $126.78 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $124.72 | 2022 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $117.38 | 2021-2023 | Belsomra, Steglatro, Verquvo |
| Inogen, INC. | $104.45 | 2022-2024 | Inogen At Home Stationary Concentrator |
| Axsome Therapeutics, INC. | $102.40 | 2023-2025 | Auvelity |
| Astellas Pharma US INC | $98.83 | 2023-2024 | Veozah |
| Alkermes, INC. | $96.64 | 2023-2024 | Lybalvi |
| Idorsia Pharmaceuticals US INC | $91.73 | 2023-2025 | Quviviq, Quviviq |
| Vanda Pharmaceuticals INC. | $80.47 | 2021-2025 | Hetlioz, Fanapt |
| Dexcom, INC. | $73.75 | 2021-2023 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $68.00 | 2022-2023 | Spravato |
| Neurocrine Biosciences, INC. | $67.13 | 2021-2024 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.67 | 2021-2025 | Jardiance |
| Inspire Medical Systems, INC. | $60.49 | 2024-2025 | Inspire |
| Paratek Pharmaceuticals, INC. | $46.55 | 2023-2025 | Nuzyra |
| Halozyme INC | $42.17 | 2023 | |
| Tactile Systems Technology INC | $36.85 | 2025 | Nimbl, Flexitouch Plus |
| Biohaven Pharmaceuticals, INC. | $36.82 | 2021 | |
| Convatec INC. | $34.88 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $34.09 | 2024-2025 | Eliquis, Camzyos |
| Eisai INC. | $33.18 | 2021-2022 | |
| Amarin Pharma, INC. | $32.51 | 2021 | |
| Sanofi-Aventis U.S. LLC | $30.46 | 2022-2023 | |
| Antares Pharma, INC. | $27.76 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Baxter Healthcare | $26.39 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Abbott Laboratories | $24.99 | 2025 | Freestyle Libre 3 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.73 | 2023 | Lifevest |
| Xeris Pharmaceuticals, INC. | $22.53 | 2024 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $22.10 | 2024-2025 | Voquezna |
| Medtronic, INC. | $20.77 | 2024 | Intellis Adaptivestim |
| Ibsa Pharma INC. | $16.92 | 2025 | Tirosint, Flector, Licart |
| Abiomed | $16.43 | 2021 | |
| Globus Medical, INC. | $16.13 | 2025 | Senza |
| Teva Pharmaceuticals USA, INC. | $14.63 | 2021 | |
| Horizon Therapeutics Plc | $14.29 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.21 | 2023 | Seglentis |
| Pharmacosmos Therapeutics INC. | $12.84 | 2021 | |
| Nevro Corp. | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.